Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

75%

6 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
6(75.0%)
Phase 1
2(25.0%)
8Total
Phase 4(6)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT05212623Phase 1Completed

A Clinical Trial of an Quadrivalent Inactivated Influenza Vaccine in Healthy Children Aged 6 to 35 Months

Role: collaborator

NCT04091880Phase 4Completed

Evaluation of the Safety and Immunogenicity of Simultaneously Administration of EV71 Vaccine and Influenza Vaccine

Role: collaborator

NCT04559204Phase 4Completed

Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4

Role: collaborator

NCT05453487Phase 4Unknown

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine (Sinopharm BBIBP-CorV) Coadministered With Rabies Vaccine

Role: collaborator

NCT04790851Phase 4Completed

Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4

Role: collaborator

NCT05079152Phase 4Unknown

Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4

Role: collaborator

NCT04612634Phase 4Unknown

Evaluation of the Safety and Immunogenicity of Hepatitis A Vaccine

Role: collaborator

NCT02603055Phase 1Completed

A Clinical Trial to Evaluate a Recombinant Hepatitis E Vaccine in Healthy Adults

Role: collaborator

All 8 trials loaded